Moderna's stock surged 176.9% to $174.38 on August 19, 2026, boosting its market cap to about $69.6 billion. The company expects to end 2026 with $4.7-$5.2 billion in cash and investments, plus a $0.9 billion credit line. CEO Stéphane Bancel highlighted Moderna's transition into a growth phase but has not indicated any immediate merger or acquisition plans. Potential acquisition targets include Immatics, Arbutus Biopharma, Intellia Therapeutics, and Editas Medicine, all players in mRNA and genetic medicine. The sector is consolidating, with recent deals by BioNTech, Eli Lilly, and Vertex, positioning Moderna as a strong bidder with increased financial power, though management emphasizes cautious spending.
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology eff...
Moderna shares surged 6% amid a broader market rotation from AI and tech stocks into healthcare, outperforming peers BioNTech and Pfizer. This rally is supported by positive clinical data from August showing Moderna's personalized mRNA cancer vaccine...
Moderna's stock has surged over 650% this year due to excitement around its personalized cancer vaccine showing promising trial results. Despite this rally, analyst price targets remain much lower than the current share price, suggesting the stock ma...
